1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Sarcopenia - Pipeline Review, H1 2016

Sarcopenia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 64 pages

Sarcopenia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Sarcopenia - Pipeline Review, H1 2016’, provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Sarcopenia
- The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects
- The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sarcopenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Sarcopenia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sarcopenia Overview 7
Therapeutics Development 8
Pipeline Products for Sarcopenia - Overview 8
Pipeline Products for Sarcopenia - Comparative Analysis 9
Sarcopenia - Therapeutics under Development by Companies 10
Sarcopenia - Therapeutics under Investigation by Universities/Institutes 11
Sarcopenia - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Sarcopenia - Products under Development by Companies 14
Sarcopenia - Products under Investigation by Universities/Institutes 15
Sarcopenia - Companies Involved in Therapeutics Development 16
GlaxoSmithKline Plc 16
MYOS Corporation 17
Neurotune AG 18
Novartis AG 19
PolyNovo Limited 20
PsiOxus Therapeutics Limited 21
Regeneron Pharmaceuticals, Inc. 22
Sumitomo Dainippon Pharma Co., Ltd. 23
Sarcopenia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
AOD-9604 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ARM-210 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
bimagrumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
BIO-101 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
BIO-103 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
DA-4210 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
espindolol - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
NEP-28 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
NT-1654 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Proteins for Musculoskeletal Disorders - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Recombinant Protein for Sarcopenia - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
S-107 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
trevogrumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Sarcopenia - Recent Pipeline Updates 51
Sarcopenia - Dormant Projects 55
Sarcopenia - Discontinued Products 56
Sarcopenia - Product Development Milestones 57
Featured News and Press Releases 57
Nov 26, 2015: Biophytis to present preclinical proof of concept for Sarcob to treat sarcopenic obesity at SCWD on December 4th 57
Nov 17, 2015: Biophytis establishes Boston subsidiary to accelerate clinical development of Sarcob 57
Sep 21, 2015: BIOPHYTIS initiates the clinical batches production of BIO101, the first step in the ongoing phase 2b trial in the sarcopenic obesity 57
Mar 13, 2012: Calzada Announces Positive Results Of AOD9604 In Cartilage And Muscle Repair Models 58
Dec 14, 2011: Calzada Announces New Applications For AOD9604 59
Dec 08, 2011: PsiOxus Therapeutics To Present Data On MT-102 At Cachexia Conference 59
Aug 02, 2011: Researchers At Columbia University Discover New Drug For Sarcopenia 60
Dec 16, 2010: Myotec Therapeutics Completes Merger With Hybrid BioSystems To Form PsiOxus Therapeutics 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables
Number of Products under Development for Sarcopenia, H1 2016 8
Number of Products under Development for Sarcopenia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Sarcopenia - Pipeline by GlaxoSmithKline Plc, H1 2016 16
Sarcopenia - Pipeline by MYOS Corporation, H1 2016 17
Sarcopenia - Pipeline by Neurotune AG, H1 2016 18
Sarcopenia - Pipeline by Novartis AG, H1 2016 19
Sarcopenia - Pipeline by PolyNovo Limited, H1 2016 20
Sarcopenia - Pipeline by PsiOxus Therapeutics Limited, H1 2016 21
Sarcopenia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 22
Sarcopenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Sarcopenia Therapeutics - Recent Pipeline Updates, H1 2016 51
Sarcopenia - Dormant Projects, H1 2016 55
Sarcopenia - Discontinued Products, H1 2016 56

List of Figures
Number of Products under Development for Sarcopenia, H1 2016 8
Number of Products under Development for Sarcopenia - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Growth Hormone Secretagogue Recepto ...

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Obesity - Pipeline Review, H2 2016

November 2016 $ 2500

Download Unlimited Documents from Trusted Public Sources

CKD - Investor Report, December 2016

  • December 2016
    23 pages
  • Therapy  

    Therapy  

  • United States  

    World  

View report >

C&C Cosmeceuticals Corporation - Company Report, November 2016

  • November 2016
    2 pages
  • Managed Care  

    Healthcare  

    Chronic Disease  

  • United States  

    Canada  

    Europe  

View report >

C&C Cosmeceuticals Corporation - Company Report, November 2016

  • November 2016
    2 pages
  • Managed Care  

    Healthcare  

    Chronic Disease  

  • United States  

    Canada  

    Europe  

View report >

Related Market Segments :

Obesity
Therapy
Pharmaceutical

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.